These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

660 related items for PubMed ID: 22630093

  • 21. Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.
    Prabhakaran K, Harris EB, Randhawa B, Adams LB, Williams DL, Hastings RC.
    Microbios; 1993; 76(309):251-61. PubMed ID: 8302203
    [Abstract] [Full Text] [Related]

  • 22. Extended spectrum beta-lactamase producing multidrug resistant urinary isolates from children visiting Kathmandu Model Hospital.
    Dhakal S, Manandhar S, Shrestha B, Dhakal R, Pudasaini M.
    Nepal Med Coll J; 2012 Jun; 14(2):136-41. PubMed ID: 23671965
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M, García-Castillo M, Bofarull AM, Cantón R, CENIT Study Group.
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE, Antibacterial Resistance Leadership Group.
    Clin Infect Dis; 2015 May 01; 60(9):1319-25. PubMed ID: 25586681
    [Abstract] [Full Text] [Related]

  • 32. Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?
    Bouxom H, Fournier D, Bouiller K, Hocquet D, Bertrand X.
    Int J Antimicrob Agents; 2018 Jul 01; 52(1):100-103. PubMed ID: 29580930
    [Abstract] [Full Text] [Related]

  • 33. [Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections].
    Eser OK, Altun Uludağ H, Ergin A, Boral B, Sener B, Hasçelik G.
    Mikrobiyol Bul; 2014 Jan 01; 48(1):59-69. PubMed ID: 24506716
    [Abstract] [Full Text] [Related]

  • 34. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children.
    Tratselas A, Iosifidis E, Ioannidou M, Saoulidis S, Kollios K, Antachopoulos C, Sofianou D, Roilides EJ.
    Pediatr Infect Dis J; 2011 Aug 01; 30(8):707-10. PubMed ID: 21248655
    [Abstract] [Full Text] [Related]

  • 35. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA, Bassetti M, Duncan LR, Castanheira M.
    J Antimicrob Chemother; 2017 May 01; 72(5):1386-1395. PubMed ID: 28165526
    [Abstract] [Full Text] [Related]

  • 36. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S, Gençer S, Batırel A, Hacıseyitoğlu D, Ozer S.
    Mikrobiyol Bul; 2014 Oct 01; 48(4):545-55. PubMed ID: 25492650
    [Abstract] [Full Text] [Related]

  • 37. Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae.
    Watkins RR, Deresinski S.
    Expert Rev Anti Infect Ther; 2017 Oct 01; 15(10):893-895. PubMed ID: 28914107
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D, Yinnon AM, Broide E, Rudensky B.
    Chemotherapy; 2007 Oct 01; 53(3):185-9. PubMed ID: 17347564
    [Abstract] [Full Text] [Related]

  • 40. Clinical significance of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae blood isolates with inducible AmpC β-lactamase.
    Cheong HS, Ko KS, Kang CI, Chung DR, Peck KR, Song JH.
    Microb Drug Resist; 2012 Aug 01; 18(4):446-52. PubMed ID: 22409779
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.